-
2023-504471-25-00
5
2024-03-01
Fibrotic Lung Disease
-
2023-503288-40-00
5
2024-01-26
Unresectable or Metastatic Melanoma
-
2022-502442-27-00
5
2024-01-08
Obesity
-
2022-502010-85-00
9
2023-12-20
Non-Squamous Non-Small Cell Lung Cancer
-
2023-503484-42-00
7
2023-10-19
Advanced, metastatic, solid malignancy
-
2023-503652-27-00
5
2023-10-06
Melanoma
-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2023-503444-13-00
5
2023-03-29
Relapsed/refractory multiple myeloma
-
2023-509320-17-00
6
2023-03-28
non-radiographic axial spondyloarthritis
-
2023-506924-94-00
5
2023-02-28
Cardiovascular disease
-
2023-506929-11-00
5
2022-10-17
Overweight and obesity
-
2024-512378-91-00
4
2022-06-24
Unresectable or Advanced Melanoma
-
2024-514723-42-00
9
2022-05-05
Locally advanced unresectable or metastatic, microsatellite instabilit
-
2023-508897-27-00
5
2022-04-28
Multiple Myeloma
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2023-510241-16-00
4
2021-12-03
Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
-
2024-511636-27-00
5
2021-12-01
Follicular Lymphoma
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-512038-13-00
5
2021-09-16
Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
-
2023-508968-30-00
5
2021-09-08
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
-
2023-507687-38-00
9
2021-08-23
Participants with extensive-stage small cell lung cancer
-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2024-516868-28-00
4
2021-05-04
Ph+ Acute Lymphoblastic Leukemia